parkinson's disease retatrutide clinical trial ly3437943 Incretin triple agonist (LY3437943) alleviates obesity-associated cancer progression Retatrutide Results: 28.3% Weight Loss – DMTs are major clinical research

Not everyone is suitable for GLP-1 therapy

The drug is working even when the scale is not moving

Key takeaways include: Obesity drug coverage in Medicaid remains limited, with 13 state Medicaid programs covering GLP-1s for obesity treatment under fee-for-service (FFS) as of January 2026

In the morning, top with fresh raspberries, a sprinkle of toasted coconut flakes, and maybe a few blueberries

DISCUSSION This review examines how GLP-1 receptor agonists have various effects on neurochemical and physiologic pathways in the brain to mitigate alcohol-seeking behavior

Clinical trials are typically short, tightly controlled, and often exclude patients with histories of depression, anxiety, or suicidal ideation